Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 3 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

33%

1 trials in Phase 3/4

Results Transparency

0%

0 of 2 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 2
1(50.0%)
Phase 3
1(50.0%)
2Total
Phase 2(1)
Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (3)

Showing 3 of 3 trials
NCT00676507Phase 3Completed

Phase III Lucanix™ Vaccine Therapy in Advanced Non-small Cell Lung Cancer (NSCLC) Following Front-line Chemotherapy

Role: lead

NCT01279798Unknown

Expanded Access Multicenter Study of Lucanix® (Belagenpumatucel-L)

Role: lead

NCT01058785Phase 2Completed

Phase II Study of Lucanix™ in Patients With Stages II-IV Non-Small Cell Lung Cancer

Role: lead

All 3 trials loaded